Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca VP Detlev Biniszkiewicz On Building An Oncology Strategy In China And Asia

This article was originally published in The Pink Sheet Daily

Executive Summary

Fresh off a global deal to in-license a novel oncology molecule discovered in China, the head of strategy for AZ’s Oncology Innovative Medicine Unit speaks with PharmAsia News during the JP Morgan Healthcare Conference about how AstraZeneca’s strategy in Asia differs from its peers.

Advertisement

Related Content

Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS
Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS
AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City
Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
AstraZeneca Rebuilds R&D Amid Growing Near-Term Pressures
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel